ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0427

Association of Menopause and Systemic Rheumatic Disease Severity in Peri-Menopausal and Menopausal Women with Systemic Rheumatic Disease

Lucy Masto1, Amaya Smole2, Ranqing Lan1, Michael Parides1, Caroline Siegel1, Sarah Lieber1, Jonah Levine1, Bessie Stamm1, Lisa Mandl1, Michael Lockshin3, Lisa Sammaritano4 and Medha Barbhaiya1, 1Hospital for Special Surgery, New York, NY, 2Hospital for Special Surgery, Amherst, MA, 3Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 4Hospital for Special Surgery, Scarsdale, NY

Meeting: ACR Convergence 2024

Keywords: rheumatoid arthritis, Systemic lupus erythematosus (SLE), Women's health

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Reproductive Issues in Rheumatic Disorders Poster

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: The relationship between menopause and systemic rheumatic disease (SRD) severity in women with SRDs is poorly understood. Few studies evaluating this association suggest worsening disease activity in RA but improved disease activity in SLE (Shah et al. Cureus, 2020); however, to our knowledge, no study directly compares SRDs. We explored the association of menopause and self-reported disease activity in women with SRDs, comparing self-reported outcomes between women with RA and SLE specifically.

Methods: We enrolled women ages 18-65 evaluated by a Hospital for Special Surgery rheumatologist ≥2 times from 2020-2022 in the Rheumatology Women’s Reproductive Health and Wellness Cohort. This analysis includes women with an SRD confirmed by ICD-10 code-based algorithms who self-reported peri-menopause or menopause and completed demographic, medical history, and menopause questionnaires. We used descriptive statistics to compare patient-reported demographics, menopause symptoms, and SRD-related measures in SLE versus RA. In secondary analyses, we stratified the cohort by those reporting worsened SRD during/after menopause vs. those who did not.

Results: Of 1,108 cohort participants, 354 (32%) had an SRD and self-reported menopause or peri-menopause (mean age: 56.7 ± 6.4 years, 267 [75.4%] White, 54 [15.3%] Hispanic or Latina/LatinX). 109 (32.8%) women with SRDs reported that their SRD “worsened/required more medication/was more severe” when asked how their condition changed during menopause, though this did not differ between women with SLE vs. RA (p=0.24). However, in RA vs. SLE, a higher proportion of peri-menopausal and menopausal women reported that their most recent SRD flare was “severe” (p< 0.01). Menopause symptoms and medication use for symptoms did not differ significantly between women with RA vs. SLE, yet women with SLE more commonly discussed issues related to menopause with their rheumatologist (37.8% vs. 16.7%, p< 0.01; Table 1). When stratified by self-report of SRD worsening during/after menopause versus not, SRD diagnosis did not differ. Women with worsening SRD reported more menopausal symptoms (84 [77.4%] vs.137 [61.4%], p< 0.01) with higher reports of neuropsychiatric symptoms (p< 0.01), urogenital symptoms (p< 0.01), and bloating (p< 0.05). They also more commonly used biologics (p=0.03), reported having a more recent SRD flare (p< 0.01), and cited concern for risk of cancer/heart disease as a reason for not using hormone replacement therapies to treat menopausal symptoms (p=0.04; Table 2).

Conclusion: Nearly a third of women with SRDs in our cohort report worsening disease associated with menopause, with this same group reporting more recent SRD flares and more menopausal symptoms. Although the association of menopause and SRD activity in SLE and RA was similar in our cohort, patients with SLE were over twice as likely to discuss menopausal issues with their rheumatologists than those with RA. Future multivariable analyses confirming these findings will help inform tailored clinical management of menopausal women with SRDs. Enhanced attention to and discussion of SRD flares and menopausal symptoms in women with SRDs may help contribute to optimizing mental and physical health.

Supporting image 1

Supporting image 2


Disclosures: L. Masto: None; A. Smole: None; R. Lan: None; M. Parides: None; C. Siegel: None; S. Lieber: None; J. Levine: None; B. Stamm: None; L. Mandl: Annals of Internal Medicine, 2, Regeneron Pharmaceuticals, 5, Wolters Kluwer, 9; M. Lockshin: None; L. Sammaritano: None; M. Barbhaiya: None.

To cite this abstract in AMA style:

Masto L, Smole A, Lan R, Parides M, Siegel C, Lieber S, Levine J, Stamm B, Mandl L, Lockshin M, Sammaritano L, Barbhaiya M. Association of Menopause and Systemic Rheumatic Disease Severity in Peri-Menopausal and Menopausal Women with Systemic Rheumatic Disease [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/association-of-menopause-and-systemic-rheumatic-disease-severity-in-peri-menopausal-and-menopausal-women-with-systemic-rheumatic-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-of-menopause-and-systemic-rheumatic-disease-severity-in-peri-menopausal-and-menopausal-women-with-systemic-rheumatic-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology